205 related articles for article (PubMed ID: 23199506)
1. Second generation direct antivirals and the way to interferon-free regimens in chronic HCV.
Lewis H; Cunningham M; Foster G
Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):471-85. PubMed ID: 23199506
[TBL] [Abstract][Full Text] [Related]
2. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
3. HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents.
Calle Serrano B; Manns MP
Antivir Ther; 2012; 17(6 Pt B):1133-46. PubMed ID: 23188760
[TBL] [Abstract][Full Text] [Related]
4. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
5. The science of direct-acting antiviral and host-targeted agent therapy.
Pawlotsky JM
Antivir Ther; 2012; 17(6 Pt B):1109-17. PubMed ID: 23188746
[TBL] [Abstract][Full Text] [Related]
6. Targets for antiviral therapy of hepatitis C.
Rupp D; Bartenschlager R
Semin Liver Dis; 2014 Feb; 34(1):9-21. PubMed ID: 24782254
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.
Hamana A; Takahashi Y; Uchida T; Nishikawa M; Imamura M; Chayama K; Takakura Y
Antiviral Res; 2017 Oct; 146():130-138. PubMed ID: 28864074
[TBL] [Abstract][Full Text] [Related]
8. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
Yang SS; Kao JH
Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
[TBL] [Abstract][Full Text] [Related]
9. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets.
Ploss A; Dubuisson J
Gut; 2012 May; 61 Suppl 1():i25-35. PubMed ID: 22504917
[TBL] [Abstract][Full Text] [Related]
10. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
Le Pogam S; Seshaadri A; Ewing A; Kang H; Kosaka A; Yan JM; Berrey M; Symonds B; De La Rosa A; Cammack N; Nájera I
J Infect Dis; 2010 Nov; 202(10):1510-9. PubMed ID: 20942646
[TBL] [Abstract][Full Text] [Related]
11. Daclatasvir for the treatment of chronic hepatitis C.
Degasperi E; Aghemo A; Colombo M
Expert Opin Pharmacother; 2015; 16(17):2679-88. PubMed ID: 26549010
[TBL] [Abstract][Full Text] [Related]
12. [Antiviral treatment of chronic hepatitis C].
Berger A
Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus and natural compounds: a new antiviral approach?
Calland N; Dubuisson J; Rouillé Y; Séron K
Viruses; 2012 Oct; 4(10):2197-217. PubMed ID: 23202460
[TBL] [Abstract][Full Text] [Related]
14. New targets for antiviral therapy of chronic hepatitis C.
Bühler S; Bartenschlager R
Liver Int; 2012 Feb; 32 Suppl 1():9-16. PubMed ID: 22212566
[TBL] [Abstract][Full Text] [Related]
15. HCV direct-acting antiviral agents: the best interferon-free combinations.
Schinazi R; Halfon P; Marcellin P; Asselah T
Liver Int; 2014 Feb; 34 Suppl 1(Suppl 1):69-78. PubMed ID: 24373081
[TBL] [Abstract][Full Text] [Related]
16. Current therapy for chronic hepatitis C: The role of direct-acting antivirals.
Li G; De Clercq E
Antiviral Res; 2017 Jun; 142():83-122. PubMed ID: 28238877
[TBL] [Abstract][Full Text] [Related]
17. Interferon free therapy with direct acting antivirals for HCV.
Asselah T; Marcellin P
Liver Int; 2013 Feb; 33 Suppl 1():93-104. PubMed ID: 23286852
[TBL] [Abstract][Full Text] [Related]
18. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
19. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
Fontaine H; Alric L; Labreuche J; Legendre B; Louvet A; Antoine C; Legendre CM; Hazzan M; Kamar N; Dharancy S; Pol S; Duhamel A; Mathurin P
J Hepatol; 2019 May; 70(5):831-838. PubMed ID: 30879789
[TBL] [Abstract][Full Text] [Related]
20. NS5A inhibitors for the treatment of hepatitis C infection.
Gitto S; Gamal N; Andreone P
J Viral Hepat; 2017 Mar; 24(3):180-186. PubMed ID: 27925362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
